Appointments at BiPar Sciences
This article was originally published in Scrip
BiPar Sciences, a private US biopharmaceutical company developing PARP inhibitors as cancer therapies, has appointed Sunil Patel vice-president of corporate development and marketing, and Adrienne Weil legal counsel. Mr Patel previously served as vice-president of corporate development at Allos Therapeutics, while Ms Weil formerly worked at the law offices of Orrick, Herrington & Sutcliffe.
You may also be interested in...
The European public assessment report for Kaftrio shows that EU regulators had concerns about whether Vertex’s triple drug combination for cystic fibrosis represented a new treatment paradigm.
Swissmedic says its good manufacturing practice certificates remain valid for longer than companies might assume. Separately, it is giving companies more time to conduct nitrosamine-related risk evaluations.
Stada has appointed a head of digital communications; PGEU elects new chair and vice-chair; and the new UK health claims committee unveils its first members.